Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269… Read more
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.59 Billion CNY
Based on the latest financial reports, Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) has total liabilities worth CN¥1.59 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jamf Holding
NASDAQ:JAMF
|
USA | $1.35 Billion |
|
Wilhelm Wilhelmsen Holding ASA
LSE:0P0T
|
UK | Nkr1.40 Billion |
|
VisEra Technologies Co. Ltd.
TW:6789
|
Taiwan | NT$3.90 Billion |
|
Test Research Inc
TW:3030
|
Taiwan | NT$2.55 Billion |
|
Redwire Corp
NYSE:RDW
|
USA | $518.20 Million |
|
PROS Holdings Inc
NYSE:PRO
|
USA | $521.11 Million |
|
Alpha Bank SA
PINK:ALBKY
|
USA | $78.11 Billion |
|
Cyrela Brazil Realty S.A. Empreendimentos e Participações
SA:CYRE3
|
Brazil | R$13.46 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.52 Billion | +134.45% |
| 2023-12-31 | CN¥647.75 Million | +100.28% |
| 2022-12-31 | CN¥323.43 Million | +14.32% |
| 2021-12-31 | CN¥282.91 Million | +107.40% |
| 2020-12-31 | CN¥136.41 Million | -22.91% |
| 2019-12-31 | CN¥176.96 Million | -- |